## **Core Concept**
The clinical presentation described for the premature neonate, including tachypnea, nasal flaring, subcostal and intercostal retractions, and specific chest radiography findings, is indicative of **Respiratory Distress Syndrome (RDS)**, formerly known as hyaline membrane disease. RDS is a leading cause of morbidity and mortality in premature infants, caused by **surfactant deficiency**.

## **Why the Correct Answer is Right**
The best treatment plan for RDS involves **surfactant replacement therapy**, which directly addresses the underlying pathophysiology of surfactant deficiency. Surfactant reduces surface tension within the alveoli, facilitating easier lung expansion and improving gas exchange. Administered as an intratracheal instillation, surfactant therapy has been shown to decrease the severity of RDS, reduce the need for mechanical ventilation, and lower the risk of complications such as air leaks and chronic lung disease.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While oxygen therapy and maintenance of a neutral thermal environment are supportive measures, they do not directly address the surfactant deficiency causing RDS.
- **Option B:** Although mechanical ventilation may be necessary for some infants with RDS, it does not treat the underlying cause and can be associated with complications like barotrauma and volutrauma.
- **Option C:** This option might seem plausible but is not specified; however, given that surfactant therapy directly addresses the deficiency, any option not involving surfactant would be less optimal.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **premature infants are at high risk for RDS** due to surfactant deficiency, and **early surfactant therapy** can significantly improve outcomes. Prophylactic surfactant administration to very preterm infants shortly after birth is a strategy used in many neonatal units to prevent RDS.

## **Correct Answer:** . **Surfactant replacement therapy**.